From the bottom of my heart, I want to thank our Upjohn colleagues for their contributions over the years and dedication in helping us achieve this milestone. They have made our company stronger and helped us deliver meaningful value to patients around the world.
I know our Upjohn colleagues will deliver the same value for @ViatrisInc, which will combine best-in-class manufacturing, science experience and proven commercial capabilities to bring quality medicines to patients.
Looking ahead at the new @pfizer, we believe our pipeline has never been stronger, and we are inspired to continue developing breakthrough treatments & delivering innovative, life-changing medicines that help us deliver on our purpose – Breakthroughs that change patients’ lives.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Very happy to say that we have more good news to share. The final efficacy analysis of @pfizer's Phase 3 study showed that our #COVID19 vaccine candidate met all of the study's primary efficacy endpoints: pfizer.com/news/press-rel…
Most notably, the vaccine candidate was shown to be 95% effective in helping prevent #COVID19 beginning 28 days after the first dose.
We also announced that the safety database required by the @US_FDA for Emergency Use Authorization (EUA) has been achieved.
Thank you @margbrennan for the great #COVID19 discussion on @facethenation this morning. Our decision to expand the Phase 3 trial would allow us to further increase population diversity as well as generate even more safety and efficacy data.
Volunteers from all over the country have raised their hands to participate, and now we want to expand to ensure we include more vulnerable populations.
We chose to fund our program without accepting taxpayer money so we could liberate our scientists from bureaucracy and allow them to focus solely on the scientific challenges.